Assessing the Impact of Scalp Cooling in With Metastatic Breast Cancer
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Eribulin (Primary) ; Sacituzumab govitecan (Primary) ; Trastuzumab-deruxtecan (Primary)
- Indications Alopecia; Chemotherapy-induced damage
- Focus Therapeutic Use
- 25 Jun 2024 Planned End Date changed from 1 Jun 2026 to 1 Jun 2028.
- 25 Jun 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2026.
- 06 Feb 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.